Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenicriviroc for Arterial Inflammation in HIV
NCT04334915Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of cenicriviroc in arteritis, atherosclerosis, sponsored by National Institute of Allergy and Infectious Diseases. Planned start Nov 2022; status: withdrawn.
02
Drugs
cenicriviroc
03
Conditions
arteritisatherosclerosis
Beyond the preview
Go deeper on NCT04334915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04334915.